Device Trial Radar · NCT07403058
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 12, 2026
Primary completion
Mar 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Axon Therapies, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 11, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a small, early-stage clinical trial designed to test whether a new catheter-based procedure is safe and may help people with heart failure with reduced ejection fraction (HFrEF). The procedure uses the Satera Ablation System to treat the right greater splanchnic nerve, which may play a role in heart failure symptoms. The study also aims to identify which types of patients might benefit most from this treatment in the future. Up to 50 patients aged 40 or older with HFrEF will take part at as many as 10 hospitals worldwide. The study is prospective, meaning patients are followed forward in time, and it is randomized, double-blinded, and sham-controlled. Patients are randomly assigned in a 2:1 ratio to either receive the actual nerve ablation treatment or a sham (placebo) procedure. Randomization happens during the procedure, after anesthesia or sedation, to reduce the risk of revealing which treatment the patient receives. Neither the patient nor their heart failure doctor will know whether the patient received the real treatment or the sham. However, the doctor performing the procedure and certain study staff will know, mainly for safety and operational reasons. The sham procedure is designed to mimic the real procedure as closely as possible without performing the nerve ablation. It involves placing a small needle in the groin or neck and accessing the vein, but no treatment catheter is inserted. The sham procedure takes about the same amount of time as the real treatment (around 45 minutes) to help account for any placebo effect. Overall, this study is focused on evaluating safety and early signs of benefit rather than proving long-term effectiveness.
Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Right Greater Splanchnic Nerve (GSN) ablationDevice
Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.
Sham ControlProcedure
Simulated procedure designed to mimic the treatment experience without delivering nerve ablation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device or procedure related serious adverse eventsTime frame: Treatment through the 1 month
- NT-proBNP (6 months)Time frame: Baseline through the 6 months
Locations
9 sites in 5 countries. Site status is shown where the registry gives one.
Motol and Homolka University Hospital
Prague, Czechia · Recruiting
Heart and Vascular Clinic
Tbilisi, Georgia · Recruiting
Tbilisi Heart Center
Tbilisi, Georgia · Recruiting
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.